# LL-37 vs Thymosin Alpha-1: Direct Antimicrobial Action Against Immune Modulation > Two immune peptides at opposite ends of the system — one acts on microbial membranes, the other on T cells. Mechanisms, evidence, handling pitfalls and how to choose. Web page: https://peptidemedixeu.com/en/learn/ll-37-vs-thymosin-alpha-1/ · Peptide Medix EU · 8 min read · Updated: 2025-11-23 Although both are immune-associated peptides, these two work at opposite poles of the immune system. LL-37 is a positively charged host-defence peptide that interacts directly with the membranes of microbes, whereas Thymosin Alpha-1 is an acidic peptide of thymic origin investigated for its influence on T-cell maturation and Toll-like receptor signalling. The first is effector chemistry; the second is regulatory signalling. Choosing between LL-37 and [Thymosin Alpha-1](https://peptidemedixeu.com/en/products/thymosin-alpha-1/) therefore depends on whether your assay reads direct antimicrobial or membrane activity, or the shaping of an immune response. Each comes as lyophilized powder with a lot-matched HPLC certificate — LL-37 in 5 and 10 mg vials, Thymosin Alpha-1 in 5, 10 and 20 mg vials. LL-37 appears under anti-inflammatory peptides, Thymosin Alpha-1 under immune peptides. Both are research [chemicals for in-vitro](https://peptidemedixeu.com/en/glossary/in-vitro/) and preclinical laboratory work only, never for human use. ## An effector molecule beside a regulatory one LL-37 acts as an effector. Its precursor hCAP18 is made by neutrophils, epithelial cells and keratinocytes, and cleavage by proteinase 3 liberates the mature 37-residue peptide where infection or injury occurs. Geometry defines what it does: a positively charged, amphipathic helix inserts into negatively charged bacterial membranes, and loss of membrane integrity is the mechanism most commonly described. This is chemistry working on a target directly, not a signal being transmitted. The peptide also has a second, messier role in the literature. It binds lipopolysaccharide, alters chemotaxis and has been reported to affect receptor-mediated immune signalling — putting it partly in the regulatory camp as well. That split personality is what makes LL-37 genuinely awkward to study cleanly, and why its assays demand more controls than most. Thymosin Alpha-1, by contrast, is entirely regulatory. It has no antimicrobial activity whatsoever; the published mechanism concerns how immune cells behave — the maturation and differentiation of T cells, and modulation of Toll-like receptor pathways, TLR2 and TLR9 in particular in the reported work. Acidic and largely lacking defined structure, it is the opposite of LL-37's charged helix in every respect that matters at the bench. ## How much evidence exists, and of what kind The two sit at different rungs of the evidence ladder, and it pays to be exact about that. LL-37's record is laboratory work: antimicrobial susceptibility and minimum inhibitory concentration testing across bacterial species, studies on breaking up biofilms, wound and epithelial repair models, and cell experiments on chemotaxis and LPS neutralisation. No LL-37 product has been approved, and human data are sparse. In the strict sense it remains a research molecule. Thymosin Alpha-1 is unusual in this catalogue for having a real clinical history. A synthetic form has been approved in several countries outside the United States for hepatitis B and hepatitis C and as a vaccine adjuvant, and some editions of the World Health Organization essential medicines list have included it. Its published record therefore contains controlled human trials as well as the usual cell and rodent studies. Two qualifications follow: those trials used pharmaceutical-grade product given under medical supervision, and they say nothing at all about research-grade powder bought as a reagent. What we supply is not that regulated article and is not offered for any human purpose. Our Thymosin Alpha-1 primer and LL-37 background piece go into each record more deeply. ## Matching the peptide to the research question ### Pick LL-37 for direct antimicrobial and membrane studies Where the endpoint is inhibition of bacterial or fungal growth, membrane permeabilisation, biofilm behaviour or LPS neutralisation, only LL-37 takes part at all — Thymosin Alpha-1 has no such activity and would serve as a negative control rather than a comparator. LL-37 is likewise the right probe for questions about host-defence peptide chemistry in general, being the only human [cathelicidin](https://peptidemedixeu.com/en/products/ll-37/) there is. ### Pick Thymosin Alpha-1 for immune-modulation readouts Where the assay records T-cell maturation markers, cytokine profiles following a defined stimulus, Toll-like receptor activation or adjuvant behaviour in an animal model, Thymosin Alpha-1 corresponds directly to the published work. It is also the more practical option for longer experiments, simply because keeping it reproducibly in solution is far easier. Groups studying the thymic peptide family more broadly often pair it [with thymalin](https://peptidemedixeu.com/en/products/thymalin/), a preparation derived from thymic extract, as a family comparator. ### Use both when you are dissecting host defence Improvement in an infection model can come from acting on the pathogen or from adjusting the host response. Since LL-37 and Thymosin Alpha-1 map almost cleanly onto those two explanations, running them as separate arms is a direct way to tell them apart — bearing in mind that LL-37 is not a pure effector, so its immunomodulatory side needs controls of its own. Both are stocked in matching 5 and 10 mg sizes, which makes molar-matched parallel preparation easy, and Thymosin Alpha-1 additionally comes as a ready-made nasal solution for format comparisons. ## Handling and storage: where they differ most Thymosin Alpha-1 is undemanding. Acidic, water-soluble and largely unstructured, it shows little tendency to aggregate, and the conventional routine suffices: keep the sealed lyophilized vial frozen, warm it to room temperature before piercing the stopper so moisture does not condense on cold powder, run diluent down the vial wall, allow it to dissolve without shaking, and aliquot for single use. LL-37 ranks among the most demanding peptides in the catalogue and warrants a protocol of its own, for three reasons. Its strong positive charge makes it stick to glass and ordinary polypropylene, so a dilute working solution may lose much of its content to the tube wall before reaching the assay — low-binding labware, and carrier protein where the assay allows, are the standard remedies. Its antimicrobial activity is also highly sensitive to ionic strength and to serum: what you measure in low-salt buffer will not be reproduced at physiological salt or in serum-containing medium, and a result obtained under one condition must never be assumed to hold under another. Finally, at higher concentrations the same amphipathic helix that breaches bacterial membranes can act on mammalian ones, so cytotoxicity and haemolysis controls belong in the design from the start rather than being bolted on later. Concentration is bench arithmetic, not a usage recommendation: 2 mL of diluent in a 5 mg vial gives 2.5 mg/mL (2,500 mcg/mL), so 250 mcg sits in 0.1 mL. Since the two peptides differ in weight (4493.33 against 3108.30 g/mol), identical mass concentrations are not identical molarities, and comparative arms must be prepared on a molar basis. See our reconstitution guide and storage guide. ## Purity, identity and certificate checks Ask for the lot-matched certificate with every vial and verify HPLC purity against a [chromatogram you can examine](https://peptidemedixeu.com/en/blog/read-peptide-coa-like-chemist/), a mass result matching the expected weight — 4493.33 g/mol for LL-37, 3108.30 g/mol for Thymosin Alpha-1 — and a lot number identical to the vial label. Each brings its own concern. LL-37 is long, heavily charged and hard to synthesise, as its price reflects; deletion sequences are the impurity class to watch for, and since it binds LPS directly, endotoxin content is a fair question for any immune-signalling assay where LPS contamination would distort the readout. Thymosin Alpha-1's defining chemical feature is the acetyl group at its N-terminus; a des-acetyl impurity is 42 Da lighter and constitutes a different molecule for the purposes of any published comparison, so [acetylation](https://peptidemedixeu.com/en/glossary/acetylation/) must be confirmed rather than presumed. Our COA guide sets out what a complete certificate should contain. ## Regulatory position Both peptides are supplied as research chemicals for laboratory use only, not for human consumption. No LL-37 product is approved anywhere. Thymosin Alpha-1 does hold prescription-medicine approval in some countries outside the United States, but that approval belongs to a regulated pharmaceutical article and not to research-grade powder. For wider context, see our immune research overview. ## Frequently asked questions ### How do LL-37 and Thymosin Alpha-1 differ? LL-37 is a cationic host-defence peptide of 37 residues — the sole human cathelicidin — whose principal described action is binding and disrupting negatively charged microbial membranes. Thymosin Alpha-1 is an acidic thymic peptide of 28 residues with no antimicrobial activity, investigated for T-cell maturation and Toll-like receptor signalling. ### Is Thymosin Alpha-1 antimicrobial? It is not. The mechanism described in the literature is immunomodulatory rather than antimicrobial, so in a bacterial growth-inhibition assay it would act as a negative control rather than a counterpart to LL-37. An antimicrobial reading attributed to it should trigger a check for contamination or a solvent artefact. ### What makes LL-37 so awkward to work with? Three things. Its strong positive charge causes adsorption onto glass and ordinary plasticware, so dilute solutions lose material to surfaces. Physiological salt and serum markedly suppress its antimicrobial activity, so results do not carry across buffer conditions. And at higher concentrations it can act on mammalian membranes, which calls for cytotoxicity and haemolysis controls. ### Does either peptide have clinical evidence in humans? Thymosin Alpha-1 does. A synthetic form is approved outside the United States for hepatitis B and C and as a vaccine adjuvant, with controlled trials behind it. Those data concern a pharmaceutical article used under medical supervision, not research powder. LL-37 has no approved product, and its record is essentially laboratory-based. ### Should endotoxin be checked when working with LL-37? For any immune-signalling assay, yes, it is a fair question. LL-37 binds lipopolysaccharide directly, so endotoxin contamination can both distort a signalling readout and tie up active peptide. Asking for endotoxin data alongside the purity certificate is prudent whenever innate immune cells are involved. ### Can the two be compared at equal milligram concentrations? No. Their masses differ considerably (4493.33 versus 3108.30 g/mol), so equal mg/mL preparations do not give equal molar concentrations. Prepare and report comparative arms in molar units, correcting the labelled mass for counter-ion and residual water. ## Related products - [Thymosin Alpha-1](https://peptidemedixeu.com/en/products/thymosin-alpha-1/): from €72 --- For laboratory research use only. This page is provided for scientific and educational information. Materials referenced here are sold strictly for in-vitro laboratory research by qualified professionals — not for human or veterinary use, and nothing on this page is medical advice.